Entrada Therapeutics Inc (TRDA) — Capital Reinvestment Ratio
Entrada Therapeutics Inc (TRDA) has a Capital Reinvestment Ratio of 0.03x as of June 2024, meaning it reinvests 0% of its operating cash flow ($39.83 Million) in capital expenditures ($1.05 Million). Check TRDA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Entrada Therapeutics Inc Capital Reinvestment Ratio (2023–2023)
This chart tracks Entrada Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see TRDA cash flow metrics.
Annual Capital Reinvestment Ratio for Entrada Therapeutics Inc (2023–2023)
Year-by-year Capital Reinvestment Ratio for Entrada Therapeutics Inc from 2023 to 2023. See Entrada Therapeutics Inc (TRDA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 0.04x | $139.80 Million | $5.61 Million | — |